2. Immunology/Inflammation Apoptosis
  3. CD20 Apoptosis
  4. DXL625

DXL625 is an autophilic CD20-targeting agent. DXL625 triggers downstream apoptosis signaling pathways dependent on intact lipid rafts and extracellular Ca2+. DXL625 induces caspase-mediated apoptosis in cancer cells and selectively targets cells in the actively proliferative S phase. DXL625 mediates complement-dependent cytotoxicity in cancer cells and primary B lymphocytes. DXL625 can be used in research related to Burkitt's lymphoma and B-cell lymphoma.

For research use only. We do not sell to patients.

DXL625

DXL625 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

DXL625 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DXL625 is an autophilic CD20-targeting agent. DXL625 triggers downstream apoptosis signaling pathways dependent on intact lipid rafts and extracellular Ca2+. DXL625 induces caspase-mediated apoptosis in cancer cells and selectively targets cells in the actively proliferative S phase. DXL625 mediates complement-dependent cytotoxicity in cancer cells and primary B lymphocytes. DXL625 can be used in research related to Burkitt's lymphoma and B-cell lymphoma[1].

Species Reactivity

Human
In Vitro

DXL625 (1-25 μg/mL; 24 h, 48 h) induces dose-dependent and time-dependent reductions in ATP content in Ramos Burkitt’s lymphoma cells, with greater potency than Rituxan at all tested concentrations (1, 5, 10, 25 μg/mL) after 24 and 48 hours of treatment[1].
DXL625 (1-25 μg/mL; 24 h) induces dose-dependent caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 30.0% of cells undergoing apoptosis at the highest tested concentration (25 μg/mL) after 24 hours of treatment[1].
DXL625 (10 μg/mL; 24 h) induces caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 24.2% of cells testing positive for activated caspases after 24 hours of treatment with 10 μg/mL DXL625[1].
DXL625 (10 μg/mL; 2 h) induces complement-dependent cytotoxicity in Ramos Burkitt’s lymphoma cells, resulting in 56.5% cell death after 2 hours of treatment with 10 μg/mL DXL625 in the presence of 5% (v/v) rabbit complement sera[1].
DXL625 (10 μg/mL; 2 h) retains complement-dependent cytotoxicity activity against primary CD19+ B-lymphocytes from healthy donor peripheral blood lymphocytes, reducing the CD19+ population to 3.1% after 2 hours of treatment with 10 μg/mL DXL625 in the presence of 5% (v/v) rabbit complement sera[1].
DXL625 (10 μg/mL; 24 h) induces enhanced NK cell-mediated antibody-dependent cellular cytotoxicity in Ramos Burkitt’s lymphoma cells, reducing normalized cell viability to 0.56 after 24 hours of treatment with 10 μg/mL DXL625 at a 6:1 effector-to-target ratio[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DXL625 Related Antibodies

Cell Viability Assay[1]

Cell Line: Ramos Burkitt’s lymphoma cells
Concentration: 1-25 μg/mL
Incubation Time: 24 h; 48 h
Result: Reduced cellular ATP content by 18.4%, 26.4%, 29.7%, and 31.1% at concentrations of 1, 5, 10, and 25 μg/mL, respectively, after 24 hours compared to vehicle-treated cells.
Reduced cellular ATP content by 36.5%, 46.3%, 48.3%, and 48.5% at concentrations of 1, 5, 10, and 25 μg/mL, respectively, after 48 hours compared to vehicle-treated cells.
Showed statistically significant reductions compared to vehicle and Rituxan at all tested concentrations and time points.

Apoptosis Analysis[1]

Cell Line: Ramos Burkitt’s lymphoma cells
Concentration: 1-25 μg/mL
Incubation Time: 24 h
Result: Induced a dose-dependent increase in apoptotic sub-G0/G1 cells: 9.5%, 21.0%, 24.9%, and 30.0% at concentrations of 1, 5, 10, and 25 μg/mL, respectively.
Showed significantly higher apoptotic cell percentages than Rituxan at the same concentrations.
Displayed apoptotic cells with reduced forward scatter and increased side scatter, consistent with apoptotic progression.

Apoptosis Analysis[1]

Cell Line: Ramos Burkitt’s lymphoma cells
Concentration: 10 μg/mL
Incubation Time: 24 h
Result: Resulted in 24.2% caspase-positive cells, which was double the rate seen with equivalent Rituxan treatment.
Showed caspase-positive cells with morphological features consistent with apoptosis, matching the sub-G0/G1 population identified by PI staining.
Gene ID

931  [NCBI]

Accession
Target

CD20/MS4A1
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DXL625 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DXL625DXL 625DXL-625CD20Apoptosislipid raftsextracellular calciumS-phase cellscomplement-dependent cytotoxicitycaspase-mediated apoptosisNK cellscancer cellsprimary B-lymphocytesantibody-dependent cellular cytotoxicityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DXL625
Cat. No.:
HY-P992349
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.